beta-Alanine
-
Subject Areas on Research
- 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
- Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
- Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis.
- Anticoagulation in atrial fibrillation.
- Anticoagulation, novel agents, and procedures: can we pardon the interruption?
- Bleeding and the new anticoagulants: strategies and concerns.
- Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
- Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
- Dabigatran abrogates brain endothelial cell permeability in response to thrombin.
- Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
- Dabigatran versus warfarin in patients with mechanical heart valves.
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
- Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
- Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.
- Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
- Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
- Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
- Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
- Idarucizumab for Dabigatran Reversal.
- Letter by Van de Werf et al regarding article, "using dabigatran in patients with stroke: a practical guide for clinicians".
- Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
- Managing new oral anticoagulants in the perioperative and intensive care unit setting.
- Netarsudil-Associated Reticular Corneal Epithelial Edema with Raised Intraocular Pressure.
- Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
- Perioperative management of patients on chronic antithrombotic therapy.
- Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
- Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
- Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
- Positive outcome after intentional overdose of dabigatran.
- Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.
- Promise of factor Xa inhibition in atrial fibrillation.
- Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series.
- Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.
- Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism.
- The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
- The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.
- Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
- Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes.
-
Keywords of People
- Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
- Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic